Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03920566
Other study ID # CCR 5039
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date May 2019
Est. completion date April 2020

Study information

Verified date April 2019
Source Royal Marsden NHS Foundation Trust
Contact Emma Foreman
Phone 0208 6426011
Email Emma.Foreman@rmh.nhs.uk
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study aims to determine the nature and significance of the theoretical drug interaction between enzalutamide (a drug used to treat prostate cancer) and the direct-acting oral anticoagulant drugs (DOACs). This will be done in two ways: a laboratory study which will take place at the University of Brighton, and a clinical study in which patients will be identified who are currently taking DOACs and are due to start treatment with enzalutamide. The activity of the DOAC will be monitored using anti-Xa levels before and after commencing treatment with enzalutamide.


Description:

Enzalutamide is an effective and well-tolerated treatment for advanced prostate cancer. Unfortunately however, enzalutamide can sometimes interact with other medicines that the patient is taking, altering their concentration in the blood-stream. Enzalutamide can do this in two ways: either by increasing the breakdown of a medicine, or by blocking a special protein, called p-glycoprotein, that pumps it out of the body. An example of a medicine whose breakdown is increased by enzalutamide is warfarin. Warfarin is used to prevent, and treat blood clots that have formed in the deep veins of the legs (deep vein thrombosis or DVT) or have become lodged in blood vessels in the lungs (pulmonary embolism or PE). As enzalutamide is known to reduce the effect of warfarin, the manufacturer advises avoiding using the two medicines together. Instead,we can use a new class of medicines called the direct oral anticoagulants, or DOACs.

DOACs have an additional advantage over warfarin in that they do not require regular monitoring with blood tests. We, and other experts in the field believe that there may be a problem using DOACs and enzalutamide together, however scientific evidence suggests that enzalutamide may stop the p-glycoprotein pump from working properly, and alter its ability to pump out a range of medicines. Other evidence suggests that under certain conditions, enzalutamide may actually increase the activity of P-glycoprotein, and reduce the concentration of other medicines in the bloodstream. However, there is no scientific evidence, or evidence from patients, that has looked directly at thecombination of enzalutamide and DOACs together. Because no routine monitoring is carried out with DOACs, we are not sure of the extent of this problem, but the consequences of over or underdosing could be serious.

We have recently generated some preliminary data in our laboratory which has the measured the extent of this interaction, but we need to repeat these experiments before we can draw any firm conclusions from them. In this pilot study, we will explore the potential interaction between enzalutamide and DOACs. First, we will measure the activity of DOACs in patients who are due to start treatment with enzalutamide using a simple, well established blood test. We will then repeat this blood test after the first month of treatment, along with regular blood tests, to determine if there has been a change in the effectiveness of the DOAC. Second, we aim to build uponour laboratory data, and examine whether brief, or prolonged exposure to enzalutamide affects the ability of p-glycoproteinto pump out DOACs.

Our aims are to

1. determine if enzalutamide interacts with DOACs in patients recruited from an advanced prostatecancer clinic

2. understand in greater detail the nature of any interaction between enzalutamide and DOACs in the laboratory

3. assess the feasibility of expanding this study to generate sufficient evidence to make recommendations for clinical practice.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 15
Est. completion date April 2020
Est. primary completion date April 2020
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Male patients aged > 18 years old

- Diagnosis of castrate resistant metastatic prostate cancer

- Due to commence treatment with enzalutamide

- Currently prescribed edoxaban, rivaroxaban or apixaban

- Calculated CrCl (Cockroft & Gault) > 30ml/min

Exclusion Criteria:

- Patients <18 years old

- Due to stop edoxaban/ rivaroxaban / apixaban during study period (i.e. within 4 weeks of recruitment)

- Currently taking other medicines which induce or inhibit P-gp or increase/reduce the effect of apixaban or rivaroxaban (e.g. verapamil, ketoconazole, itraconazole, voriconazole, ritonavir, clarithromycin, erythromycin (refer to appendix 1 for complete list)

- Currently taking any herbal/complimentary medicines (other than homeopathic products)

- Calculated CrCl (Cockroft & Gault) <30ml/min

- Severe hepatic impairment (Childs-Pugh class C)

- Lacks capacity, including patients with documented dementia (or psychometric marker e.g. Abbreviated Mental Test Score (AMTS) <7/10) or inability to give informed consent for study participation.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Anti-Xa level
Anti-Xa level taken before commencing enzalutamide and repeated after 4 weeks of treatment

Locations

Country Name City State
n/a

Sponsors (3)

Lead Sponsor Collaborator
Royal Marsden NHS Foundation Trust Pharmacy Research UK, University of Brighton

Outcome

Type Measure Description Time frame Safety issue
Primary Anti-Xa level Difference between anti-Xa levels taken at two time points (baseline and 4-weeks after commencing enzalutamide) time 0 and time 4 weeks
Primary Efflux ratio (with enzalutamide) Difference in efflux ratio for edoxaban/ rivaroxaban / apixaban in the absence/presence of enzalutamide over a range of concentrations Each experiment will be conducted over a period of <1 day
Primary Efflux ratio (with enzalutamide and positive control) Difference in efflux ratio for edoxaban/ rivaroxaban / apixaban in the presence of enzalutamide and a positive control (e.g. verapamil, whilst ensuring appropriate statistical power) Each experiment will be conducted over a period of <1 day
Secondary Bleeding Common Terminology Criteria for Adverse Events (various types of bleeding or hemorrhage are listed. The most appropriate will be selected and graded 1-5 where Grade 1=Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated.
Grade 2=Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living.
Grade 3 = Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living.
Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to adverse event
4 weeks
Secondary Bruising A finding of injury of the soft tissues or bone characterized by leakage of blood into surrounding tissues. Graded according to Common Terminology Criteria for Adverse Events grades 1-2 where grade 1=localized or in a dependent area and grade 2 = generalize bruising 4 weeks
Secondary Venous Thromboembolism Common Terminology Criteria for Adverse Events (various different thromboembolic events are listed. The most appropriate will be selected and graded 1-5 where Grade 1=Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated.
Grade 2=Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living.
Grade 3 = Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living.
Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to adverse event
4 weeks
See also
  Status Clinical Trial Phase
Completed NCT04645940 - Fruquintinib Food Effect and Proton Pump Inhibitor Study Phase 1
Completed NCT04540965 - Impact of a Histamine H2 Receptor Antagonist (H2RA) on the Pharmacokinetics (PK) of Telaglenastat in Healthy Subjects Phase 1
Completed NCT04531072 - Effect of Atazanavir-ritonavir on the Pharmacokinetics and Toxicity of Lumefantrine Phase 4
Completed NCT03385525 - Study to Evaluate the Effect of UGT Inhibition by Valproic Acid on the Pharmacokinetics of BIIB074 Phase 1
Completed NCT05680792 - Pharmacokinetic Interaction Between Nitazoxanide and Atazanavir/Ritonavir in Healthy Volunteers N/A
Completed NCT05137548 - A Drug-Drug Interaction Study Between ATI-2173 and Tenofovir Disoproxil Fumarate in Healthy Subjects Phase 1
Not yet recruiting NCT05525351 - The Application and Validation of Triple Drug Response Surface Models on Density Spectral Array in Clinical Anesthesia
Terminated NCT01980342 - Pharmacokinetics and Pharmacodynamics of the Etonogestrel Contraceptive Implant When Co-administered With Efavirenz Phase 4
Completed NCT04080596 - DDI Study to Investigate the Impact of Itraconazole on the Pharmacokinetics of Dorzagliatin Phase 1
Recruiting NCT04593680 - Assessment of Drug-drug Interactions Between Masculinizing Hormone Therapy and Antiretroviral Agents Concomitantly for Pre-exposure Prophylaxis Among Transgender Men N/A
Active, not recruiting NCT04590417 - Assessment of Drug-drug Interactions Between Feminizing Hormone Therapy and Emtricitabine/Tenofovir Alafenamide Concomitantly for Pre-exposure Prophylaxis Among Transgender Women N/A
Completed NCT05633147 - Effect of Clarithromycin on PK of Linaprazan, Linaprazan on PK of Clarithromycin and Linaprazan on PK of Midazolam Phase 1
Completed NCT02391688 - Evaluation of the Potential Pharmacokinetic Interactions Between Probe Drugs in the Geneva Phenotyping Cocktail Phase 1
Completed NCT00806299 - Loperamide Grapefruit Juice Interaction PK Trial Phase 1
Completed NCT03336346 - Effect of Dolutegravir on Etonogestrel Levels in HIV-infected Women in Botswana
Completed NCT04818086 - Drug-drug Interaction Study of Lemborexant as an Adjunctive Treatment for Buprenorphine/Naloxone for Opioid Use Disorder Phase 1/Phase 2
Completed NCT03187015 - A Study to Examine the Effects of Entinostat on Midazolam in Healthy Adult Subjects Phase 1
Not yet recruiting NCT04463576 - Drug Interactions in Hospital Information System. The PRoSIT System..
Completed NCT03011996 - To Investigate PK and PD of CJ-12420, Clarithromycin, Amoxicillin After Multiple Dose Administration Phase 1
Completed NCT04902105 - Drug-Drug Interaction Study to Evaluate the Effect of Inhibition of UGTs on the PK of Ecopipam and Its Active Metabolite Phase 1